Lisa Salvatore - Concepedia

Author

Lisa Salvatore

Azienda Ospedaliera Universitaria Pisana ORCID

Also Known As

Carlotta Antoniotti, L SALVATORE, L Salvatore, L. Salvatore, LISA SALVATORE, Lisa Salvatore, Lorenzo Aiello Paolo Salvatore, Luca Salvatore, Salvatore, Lisa

480

Publications

7.7K

Citations

H-Index

Concepts

All Affiliations

Azienda Ospedaliera Universitaria Pisana University of Pisa Istituto Oncologico Veneto Istituti di Ricovero e Cura a Carattere Scientifico Agostino Gemelli University Polyclinic

About

Lisa Salvatore is an author at Azienda Ospedaliera Universitaria Pisana specializing in medicine, oncology, and colorectal cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	38	2.3K
2	Health Sciences	7	7	438
3	Cell Biology	3	3	197
4	Biostatistics	2	2	82
5	Public Health	1	1	13

Lisa Salvatore

Publications

6.6K

Citations

H-Index

Page 1

	Year	Citations
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer Fotios Loupakis, Chiara Cremolini, Gianluca Masi, New England Journal of Medicine	2014	1.1K
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer Fotios Loupakis, Annamaria Ruzzo, Chiara Cremolini, British Journal of Cancer	2009	557
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12C Marwan Fakih, Lisa Salvatore, Taito Esaki, New England Journal of Medicine	2023	294
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, The Lancet Oncology OncologyClinical TrialsColorectal CancerPathologyUpfront Folfoxiri	2022	246
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial Gianluca Masi, Fotios Loupakis, Lisa Salvatore, The Lancet Oncology OncologyGastrointestinal OncologyMedicineColorectal CancerPathology	2010	240
High Concordance of <i>KRAS</i> Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice Daniele Santini, Fotios Loupakis, Bruno Vincenzi, The Oncologist	2008	228
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest Chiara Cremolini, Fotios Loupakis, C. Antoniotti, Annals of Oncology Early Tumor ShrinkageMedicineColorectal CancerPathologyNord Ovest	2015	191
Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis Gianluca Masi, E. Vasile, Fotios Loupakis, JNCI Journal of the National Cancer Institute	2010	188
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer Fotios Loupakis, Chiara Cremolini, Lisa Salvatore, European Journal of Cancer Gastrointestinal OncologyMedicinePharmacologyPathologyColorectal Cancer	2013	185
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial Gianluca Masi, Lisa Salvatore, Luca Boni, Annals of Oncology Gastrointestinal OncologyMedicineRandomized Bebyp TrialColorectal CancerPathology	2015	164

Page 1